AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $46.1250.

Several research firms have weighed in on ANAB. Guggenheim restated a "buy" rating and set a $90.00 target price (up from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. HC Wainwright upgraded AnaptysBio from a "neutral" rating to a "buy" rating and upped their target price for the stock from $22.00 to $38.00 in a research note on Wednesday, June 4th. Wedbush upped their target price on AnaptysBio from $40.00 to $45.00 and gave the stock an "outperform" rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. upped their target price on AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Finally, UBS Group reissued a "neutral" rating and set a $20.00 price objective (up previously from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th.

Insider Buying and Selling at AnaptysBio

In related news, Director Hollings Renton sold 20,925 shares of the firm's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total transaction of $493,202.25. Following the sale, the director owned 4,965 shares of the company's stock, valued at $117,025.05. This trade represents a 80.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 33.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AnaptysBio

Several hedge funds have recently modified their holdings of the company. Wellington Management Group LLP boosted its holdings in shares of AnaptysBio by 0.8% during the 4th quarter. Wellington Management Group LLP now owns 66,467 shares of the biotechnology company's stock valued at $880,000 after acquiring an additional 528 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of AnaptysBio by 2.7% during the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company's stock valued at $574,000 after acquiring an additional 826 shares in the last quarter. Virtus ETF Advisers LLC boosted its holdings in shares of AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 936 shares in the last quarter. US Bancorp DE boosted its holdings in shares of AnaptysBio by 126.5% during the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 979 shares in the last quarter. Finally, Corton Capital Inc. boosted its holdings in shares of AnaptysBio by 12.2% during the 2nd quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company's stock valued at $266,000 after acquiring an additional 1,305 shares in the last quarter.

AnaptysBio Trading Down 0.7%

NASDAQ ANAB traded down $0.14 on Tuesday, hitting $20.22. 257,922 shares of the company's stock were exchanged, compared to its average volume of 483,118. The stock has a 50-day moving average of $23.64 and a 200-day moving average of $20.69. AnaptysBio has a 52 week low of $12.21 and a 52 week high of $40.70. The stock has a market cap of $566.16 million, a price-to-earnings ratio of -4.51 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.50) by $0.16. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%.The firm had revenue of $22.26 million during the quarter, compared to analysts' expectations of $11.55 million. As a group, analysts predict that AnaptysBio will post -6.08 earnings per share for the current year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.